Study of ABSK021 for chronic graft-versus-host disease
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had a stem cell or bone marrow transplant from a donor.
- You have already tried at least one treatment for your chronic graft-versus-host disease (cGvHD).
- If you are on steroids or other immune-suppressing drugs, your dose has been stable for at least 2 weeks.
- You have not had more than 5 prior treatments for cGvHD.
- You do not have an active infection or a history of reaction to the study drug's ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
This study tests a new medication called belumosudil to see how safe it is for people with chronic graft-versus-host disease (cGVHD). If you have had a stem cell transplant and still need treatment for cGVHD after trying other therapies, this trial may be an option.
This trial tests a new medicine called CK0802 for patients whose graft versus host disease (a complication after bone marrow transplant) did not improve with standard steroid treatment. The goal is to see if CK0802 can help control this condition when steroids alone haven't worked.
This study tests a combination of three drugs—high-dose cyclophosphamide, bortezomib, and abatacept—after a donor stem cell transplant to see if they can better prevent graft-versus-host disease (a condition where donor cells attack the body).
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.